Related Experiment Video

Updated: May 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

The Connexin37 gene C1019T polymorphism and risk of coronary artery disease: a meta-analysis

Zhijun Wu1, Yuqing Lou2, Wei Jin1

  • 1Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

Archives of Medical Research
|December 17, 2013
PubMed

Insights

The Connexin37 C1019T polymorphism is not linked to coronary artery disease (CAD) risk overall. However, the 1019T allele is a moderate risk factor for myocardial infarction (MI), with diabetes mellitus potentially explaining study variations.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology
  • Molecular Biology

Background:

  • The Connexin37 C1019T polymorphism is hypothesized to increase coronary artery disease (CAD) susceptibility.
  • Previous studies on this association have produced conflicting results, necessitating further investigation.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis investigating the association between the Connexin37 C1019T polymorphism and the risk of coronary artery disease (CAD).

Main Methods:

  • A meta-analysis was performed on 11 studies involving 5535 CAD patients and 5626 controls.
  • Data were analyzed using a random-effects model to calculate odds ratios and confidence intervals.
  • Publication bias was assessed using Egger's test, Begg-Mazemdar test, and funnel plots.

Main Results:

  • The C1019T polymorphism was not significantly associated with overall CAD risk (p = 0.34).
  • However, the 1019T allele showed a significant association with an increased risk of myocardial infarction (MI) (p < 0.001).
  • Meta-regression suggested that varying proportions of diabetes mellitus (DM) across studies contributed significantly to heterogeneity (p = 0.014).

Conclusions:

  • The Connexin37 C1019T polymorphism may represent a moderate risk factor specifically for myocardial infarction (MI).
  • Diabetes mellitus (DM) is identified as a likely source of heterogeneity in studies examining this genetic polymorphism and cardiovascular disease risk.
Abstract

Keywords:
ConnexinCoronary artery diseaseMyocardial infarctionPolymorphism Meta-analysis

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K